According to the Canadian Venture Capital and Private Equity Association’s (CVCA) 2024 VC market overview, investments ...
AstraZeneca has unveiled plans to invest around ... AZ announced a C$500 million investment in its Global Clinical Hub in Mississauga, Ontario, to expand its research and clinical trials ...
Canadian VC saw $7.86 billion invested across 592 deals in 2024, per the CVCA, buoyed by later-stage megadeals while seed ...
Medpage Today on MSN5d
Cancer Diagnoses Cluster in Bleeders on Anticoagulation TherapyCancer diagnoses tended to arise more in patients who bled on oral anticoagulants (OACs), a Canadian population-based cohort ...
Hosted on MSN3d
Today-History-Mar02Today in History for March 2: ...
AstraZeneca is paying $160 million for FibroGen’s China business, giving the U.K.-based Big Pharma the regional rights to oral anemia drug roxadustat. The two companies' relationship around ...
allAfrica.com on MSN3d
Africa: Ovarian Cancer Costs Countries Over $70 Billion Annually, According to a Groundbreaking Global Study by the World Ovarian Cancer CoalitionThe World Ovarian Cancer Coalition (the Coalition) announced today the publication of a first-of-its-kind study that reveals ...
FibroGen sells its China unit to AstraZeneca for about $160M, strengthening its cash position and extending its financial runway into 2027. AstraZeneca gains full rights to roxadustat in China ...
AstraZeneca is a company with a turbulent history but, for now, a promising future. We take a look at the company's story, from its creation as a merger of two equals, to its recent major ...
The FDA posted to its site the observations made during an inspection of an AstraZeneca (AZN) manufacturing center that was conducted from May 30, 2024 to June 7, 2024, including manufacturing and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback